Market Research Report
Global Neonatal Biotinidase Treatment Market - 2021-2028
|Global Neonatal Biotinidase Treatment Market - 2021-2028|
Published: October 11, 2021
Content info: 180 Pages
Delivery time: 2 business days
The global Neonatal Biotinidase Treatment market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Biotinidase deficiency, the major cause of late-onset multiple carboxylase deficiency, is an autosomal recessively inherited disorder. Biotinidase's absent or deficient activity causes it to release biotin (also known as vitamin B7 or H) from dietary proteins. Newborn screening of Biotinidase activity from dried blood spots can identify affected patients shortly after the birth.
The Neonatal Biotinidase Treatment market growth is driven by the high prevalence rate of biotinidase deficiency, growing government initiatives to increase awareness regarding hereditary neonatal diseases and rising demand for early disease detection tests across the globe.
Biotinidase deficiency is an autosomal recessive disorder caused by variants in the biotinidase gene (BTD). Age of onset and clinical phenotype varies among individuals depending on the amount of residual biotinidase activity. According to the NORD, National Organisation for Rare Diseases, it is estimated that fewer than 70 babies are born with this condition each year in the United States. Approximately 1 in 120 people are carriers of one gene for BTD, but this number may be higher in the Hispanic population and lower in the African American population. Profound biotinidase deficiency occurs in approximately 1 in 137,000 live births, and partial biotinidase deficiency occurs in approximately 1 in 110,000 live births, resulting in a combined incidence of about 1 in 61,000. The carrier frequency for biotinidase deficiency within the general population is about 1 in 120.
The health care service infrastructure is limited concerning the interconnections among primary care professionals and subspecialists, particularly in rural areas. There are geographic limitations in the availability of specific expertise for many of the rare conditions, and considerable needs exist throughout the health care system in training and education about the disorders detected through newborn screening programs.
Since the outbreak of the COVID-19 virus in 2019 December, over 100 countries across the world have been affected, and the World Health Organization has announced it a public health emergency. According to the World Health Organization report, Coronavirus (COVID-19) has infected more than 143 million individuals worldwide as of April 21, 2021.
COVID-19 has affected the economy in three main ways; firstly, by affecting production and demand, then by creating disruptions in distribution channels, and lastly, through the financial impact on firms and financial markets. Due to lockdowns across the nations, several countries such as India, China, Saudi Arabia, Egypt, UAE, and others face problems concerning drug transportation. For instance, in April 2020, Chinese suppliers stopped supplies of newborn screening kits and reagents to India due to a hampered supply chain.
Supply chain and activities related to manufacturing in the U.S., India, Spain, Italy, and U.K. was disrupted due to the implementation of lockdowns by various governments for few months, while countries such as Egypt, UAE, Saudi Arabia, and others have been facing problems with regards to transportation of kits and instruments used for newborn screening.
Vitamin B plays an essential role in maintaining good health and well-being. As the building blocks of a healthy body, vitamins B directly impact energy levels, brain function, and cell metabolism. It is essential for women who are pregnant and breastfeeding. These vitamins aid in fetal brain development as well as reduce the risk of congenital disabilities. And for expectant mothers, vitamin B may boost energy levels and lower the risk of developing preeclampsia.
Children with biotinidase deficiency (BIOT) often require lifelong treatment with biotin supplements. This is a natural vitamin found in food, but children with BIOT might not have enough of it in their bodies. Biotin supplements can help a baby's body break down the fats, proteins, and carbohydrates found in food. For instance, according to the Global Coalition on Aging study, November 2020, the prevalence of malnutrition in the hospitalized patient was around 31%. As a result, the increasing malnutrition cases is expected to increase the demand for biotin supplements, which will help the growth of this market.
Biotinidase deficiency is a rare disorder. The early-onset form (profound BTD) usually begins during the newborn (neonatal) period. Profound biotinidase deficiency refers to situations where enzyme activity is 10% or less. According to the National Organization for Rare Disorders (NORD), One in 140,000 people have profound biotinidase deficiency. Approximately 1 in 120 people are carriers of one gene for BTD, but this number may be higher in the Hispanic population and lower in the African American population.
North America accounts for the largest market share due to the increasing prevalence of biotinidase deficiency and research and development activities. The incidence of biotinidase deficiency has been reported as follows: profound biotinidase deficiency (<10% activity) 1 in 112,000, partial deficiency (10%-30% activity) 1 in 129,000, and profound and partial deficiency together 1 in 60,000. Symptoms include seizures and possible skin disorders, developmental delays, speech problems, and possible vision and hearing difficulties.
Moreover, The Washington State Department of Health, Office of Newborn Screening (NBS) tests all infants born in Washington for many rare but treatable disorders using a dried blood spot specimen. Infants with these disorders usually appear healthy at birth and, without screening, the disorders are not likely to be detected and treated in time to prevent death or severe disability. Newborn screening is one of the most successful public health initiatives in the USA.
The global Neonatal Biotinidase Treatment market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Mericon Industries, Inc, KLAIRE LABS, Merck KGaA, BIOVENCER HEALTHCARE PRIVATE LIMITED, Biogena, Natrol LLC, Pure Encapsulations, LLC, SBRNUTRITION, Life Garden Naturals and Nutra Zone Health Care. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
The global Neonatal Biotinidase Treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.